Rhodes Pharms Company Profile
What is the competitive landscape for RHODES PHARMS
RHODES PHARMS has twenty-nine approved drugs.
There are two tentative approvals on RHODES PHARMS drugs.
Summary for Rhodes Pharms
| US Patents: | 0 |
| Tradenames: | 21 |
| Ingredients: | 19 |
| NDAs: | 29 |
Drugs and US Patents for Rhodes Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhodes Pharms | FENOFIBRATE | fenofibrate | TABLET;ORAL | 076433-002 | May 13, 2005 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Rhodes Pharms | FENOFIBRATE | fenofibrate | TABLET;ORAL | 076433-001 | May 13, 2005 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Rhodes Pharms | THEOPHYLLINE | theophylline | TABLET, EXTENDED RELEASE;ORAL | 040086-001 | Apr 15, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Rhodes Pharms | ACETAMINOPHEN AND CODEINE PHOSPHATE | acetaminophen; codeine phosphate | TABLET;ORAL | 089673-002 | Feb 10, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Rhodes Pharms | METHYLPHENIDATE HYDROCHLORIDE | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 214111-002 | May 31, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Rhodes Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Rhodes Pharms | APTENSIO XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 205831-007 | Apr 17, 2015 | 10,463,624 | ⤷ Start Trial |
| Rhodes Pharms | APTENSIO XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 205831-001 | Apr 17, 2015 | 10,463,624 | ⤷ Start Trial |
| Rhodes Pharms | APTENSIO XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 205831-004 | Apr 17, 2015 | 10,463,624 | ⤷ Start Trial |
| Rhodes Pharms | DILAUDID | hydromorphone hydrochloride | TABLET;ORAL | 019892-002 | Nov 9, 2007 | 6,589,960 | ⤷ Start Trial |
| Rhodes Pharms | APTENSIO XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 205831-006 | Apr 17, 2015 | 10,463,624 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for RHODES PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 10 mg | ➤ Subscribe | 2015-12-24 |
| ➤ Subscribe | Extended-release Capsules | 30 mg | ➤ Subscribe | 2016-03-28 |
| ➤ Subscribe | Injection | 2 mg/mL | ➤ Subscribe | 2011-06-22 |
| ➤ Subscribe | Extended-release Capsules | 60 mg | ➤ Subscribe | 2015-12-23 |
| ➤ Subscribe | Extended-release Capsules | 15 mg, 20 mg, 40 mg and 50 mg | ➤ Subscribe | 2015-12-28 |
| ➤ Subscribe | Oral Solution | 5 mg/5mL | ➤ Subscribe | 2011-02-25 |
| ➤ Subscribe | Tablets | 2 mg, 4 mg, and 8 mg | ➤ Subscribe | 2013-08-05 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
